Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does CD95 have tumor promoting activities?

Marcus E Peter1, Patrick Legembre, Bryan C Barnhart

  • 1The Ben May Institute for Cancer Research, The University of Chicago, Chicago, IL 60637, USA. mpeter@uchicago.edu

Biochimica Et Biophysica Acta
|May 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Soluble CD95L triggers Caspase-10-driven reactive oxygen species production in neutrophils and aggravates anti-neutrophil cytoplasmic antibody-vasculitis.

Nature communications·2026
Same author

Developing a pan cancer therapy based on DISE-inducing short RNAs.

Molecular therapy. Nucleic acids·2026
Same author

Protein-fragment complementation assays to analyze the CD95 complex.

Methods in cell biology·2026
Same author

Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy.

Nature communications·2025
Same author

Soluble CD95L is a prognostic marker in central nervous system posttransplant lymphoproliferative disorders.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025
Same author

CD95/Fas stoichiometry in future precision medicine.

Cell death and differentiation·2025
Same journal

Cumulative Contents.

Biochimica et biophysica acta·2020
Same journal

Molecular Basis of Disease Cumulative Contents.

Biochimica et biophysica acta·2020
Same journal

General Subjects Cumulative Contents.

Biochimica et biophysica acta·2020
Same journal

Erratum to 'on the role of exchangeable hydrogen bonds for the kinetics of P680<sup>+·</sup> Q<sub>A</sub> <sup>-·</sup> formation and P680<sup>+·</sup> Pheo<sup>-·</sup> recombination in photosystem II' [Biochim. Biophys. Acta 1276 (1996) 35-44].

Biochimica et biophysica acta·2019
Same journal

Oligomeric state of the light-harvesting complexes B800-850 and B875 from purple bacterium Rubrivivax gelatinosus in detergent solution.

Biochimica et biophysica acta·2019
Same journal

Regulation of pigment content and enzyme activity in the cyanobacterium Nostoc sp. Mac grown in continuous light, a light-dark photoperiod, or darkness.

Biochimica et biophysica acta·2019
See all related articles

CD95 (APO-1/Fas) can suppress tumors but mutations can activate cancer-promoting pathways. This highlights CD95

Area of Science:

  • Cell Biology
  • Cancer Research
  • Immunology

Background:

  • CD95 (APO-1/Fas) induces apoptosis and is crucial in eliminating tumor cells.
  • Altered CD95 expression or mutations are common in human cancers, impacting apoptosis sensitivity.
  • CD95 has been considered a tumor suppressor due to its role in apoptosis induction.

Purpose of the Study:

  • To investigate the dual role of CD95 in cancer, acting as both a tumor suppressor and promoter.
  • To elucidate the mechanisms by which CD95 mutations can lead to cancer progression.
  • To propose a new model for CD95 function in advanced human cancers.

Main Methods:

  • Analysis of CD95 expression and mutations in human cancer samples.
  • Investigation of CD95 signaling pathways, including non-apoptotic pathways.

Related Experiment Videos

  • Functional studies on the impact of CD95 mutations on apoptosis resistance and tumorigenesis.

    • Main Results:

    • Downregulation or mutation of CD95 can lead to cancer cell resistance to apoptosis.
    • Increased CD95L can trigger non-apoptotic CD95 signaling, activating NF-kappaB and MAP kinases.
    • A single point mutation in CD95 can convert its function from tumor suppressor to tumor promoter.

    Conclusions:

    • CD95's role in cancer is complex, depending on its mutation status and expression levels.
    • Mutated CD95, particularly in advanced cancers, can promote tumor growth and survival.
    • Understanding CD95's dual function is critical for developing effective cancer therapies.